Evidence map›Paper›PMID 26083769›Full record

Trial reportJournal of alternative and complementary medicine (New York, N.Y.)2015

Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study.

Raoul Saggini, Alexandra Di Stefano, Ira Dodaj, Laura Scarcello, Rosa Grazia Bellomo

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of alternative and complementary medicine (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Efficacy of Piroxicam Mesotherapy in Treatment of Knee Osteoarthritis: A Randomized Clinical Trial.Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
  12. Review
  13. Review
  14. Therapeutic Effectiveness and Safety of Mesotherapy in Patients with Osteoarthritis of the Knee.Evidence-based complementary and alternative medicine : eCAM · 2018
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Raoul Saggini1 Department of Medical Science Oral and Biotechnology, G. D'Annunzio University , Chieti, Italy .
Alexandra Di Stefano2 School of Specialties in Physical Medicine and Rehabilitation, G. D'Annunzio University , Chieti, Italy .
Ira Dodaj2 School of Specialties in Physical Medicine and Rehabilitation, G. D'Annunzio University , Chieti, Italy .
Laura Scarcello2 School of Specialties in Physical Medicine and Rehabilitation, G. D'Annunzio University , Chieti, Italy .
Rosa Grazia Bellomo3 Department of Medicine and Science of Aging, G. D'Annunzio University , Chieti, Italy .
University of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPes anserine bursitis strongly affects quality of life in patients with osteoarthritis. Treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), physiotherapy, and injections of corticosteroid, with highly variable responses; recovery can take 10 days to 36 months. Mesotherapy is a minimally invasive technique consisting of subcutaneous injections of bioactive substances. The goal is to modulate the pharmacokinetics of the injected substance and prolong the effects at a local level.

objectiveTo evaluate the effects of mesotherapy with diclofenac for anserine bursitis associated with knee osteoarthritis.

methodsOne hundred and seventeen patients with anserine bursitis associated with grade II Kellgren-Lawrence knee osteoarthritis, assessed by clinical, radiographic, and ultrasonographic examination, were evaluated and treated. They were randomly divided into two groups (A, mesotherapy; B, control). Group A completed nine sessions of mesotherapy with sodium diclofenac (25 mg/1 mL; Akis®, IBSA, Lugano, Switzerland), 1 mL for each session, three times per week. Group B received 21 oral administrations of sodium diclofenac (50 mg; Voltaren®, Novartis, Parsippany, NJ), once a day for 3 weeks. Primary outcome measures were pain intensity assessed by visual analogue scale (VAS), along with ability to perform activities of daily living, ability to participate in sports, level of pain, symptoms, and quality of life, as assessed by the Knee injury and Osteoarthritis Outcome Score. These measures were performed before and after the treatment period and at 30 and 90 days' follow up.

resultsIn both groups pain level decreased significantly after the treatment period. Ultrasonography showed a reduction of the hypoechoic area related to anserine bursitis only in group A.

conclusionAdministration of conventional NSAIDs (diclofenac) by mesotherapy is effective in managing anserine bursitis in knee osteoarthritis in the short term and mid-term. These observations could be of interest for efforts to reduce the adverse effects of oral administration of anti-inflammatory drugs.

Indexed as

MesotherapyAdolescentAdultAnalysis of VarianceAnti-Inflammatory Agents, Non-SteroidalBursitisDiclofenacFemaleHumansInjections, SubcutaneousMaleMiddle AgedOsteoarthritis, KneePain MeasurementQuality of LifeYoung AdultAnti-Inflammatory Agents, Non-SteroidalDiclofenac

Identifiers

PMID26083769
PMCPMC4522948
OpenAlexW1906589171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.